An internal medicine physician on Sermo captured this measured approach, A drug like retatrutide has the potential to be a real breakthrough
DPP-4 Inhibitors In addition to their glucose-lowering effects, potential mechanisms for dipeptidyl peptidase-4 (DPP-4) inhibitors CV effect include increased ischemia tolerance, improved endothelial function, decreased expression of inflammatory cytokines, and decreased platelet aggregation
DFS Results iCRT arm: 68.3% at 3 years
We focus on small-batch synthesis, which allows for impeccable quality control
Finally, a 26-week, double-blind trial evaluated the efficacy and safety of ertugliflozin in T2DM patients who were inadequately controlled (HbA1c, 7.010.5%) after a minimum of 8 weeks of metformin therapy ( 1500 mg/day) [55]